TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Analysis: Gates Foundation's vaccine trial in RI sparks concern
Change text size
Gift Premium Articles
to Anyone
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
In this file photo taken on Sep. 26, 2018 Bill Gates and his wife Melinda Gates introduce the Goalkeepers event at the Lincoln Center in New York.Earlier this month the Bill and Melinda Gates Foundation committed up to $100 million for the global response to the outbreak (AFP/Ludovic Marin) (AFP/Ludovic Marin)
T
he Bill & Melinda Gates Foundation has renewed its long-standing partnership with Indonesia following a high-profile visit by Bill Gates to Jakarta in early May. While the Foundation emphasized its commitment to improving public health and healthcare access in the country, one initiative in particular—trials for a novel tuberculosis (TB) vaccine—has attracted growing public skepticism and concern.
Since first establishing its presence in Indonesia in 2009, the Gates Foundation has played a key role in supporting a range of national development priorities. Known globally for its focus on healthcare, the Foundation has also provided support in fields such as agriculture, education, and technological development. Over the past 15 years, it has committed more than US$300 million in grants across these sectors in Indonesia alone.
In the most recent phase of funding, the Foundation announced a total of US$159 million (Rp 2.5 trillion) in grants. The lion’s share of this new funding—around US$119—will be allocated to the health sector. These funds will support programs aimed at boosting immunization coverage, strengthening healthcare systems, and expanding access to essential medical services. An additional US$5 million each will go toward agriculture and technology initiatives, while the remaining US$28 million is earmarked for a range of social programs that cut across multiple sectors.
During a meeting at the Merdeka Palace, President Prabowo Subianto and Bill Gates agreed to conduct trials for a new TB vaccine in Indonesia, as part of broader efforts to curb the spread of communicable diseases such as polio, measles, and malaria. However, the announcement quickly drew criticism on social media, with many Indonesians expressing unease about the safety of the trial vaccine, citing concerns that it has not completed clinical testing.
Health Minister Budi Gunadi Sadikin responded by assuring the public that the vaccine is backed by scientific research and emphasized that similar vaccination programs have been carried out in the past, such as during the COVID-19 pandemic. Still, health experts have urged the government to establish clear regulations and a robust monitoring system to detect potential side effects and ensure that the clinical trials are conducted transparently and ethically.
The urgency of addressing TB in Indonesia is underscored by data from the Global TB Report 2024, which places the country as having the second highest TB burden in the world after India. An estimated 1 million Indonesians contract TB each year, with approximately 1.09 million cases going and around 125,000 deaths annually.
In addition to the health agenda, Gates also praised Indonesia’s progress in improving food security. He highlighted the country's efforts to enhance agricultural resilience, particularly through systems designed to withstand climate change and global supply chain disruptions. He also praised the government’s ongoing efforts in tackling malnutrition and expanding access to basic healthcare services, which he described as essential to building long-term societal resilience.
